Latest Phase 3 Data for First-in-Class TREMFYA®▼ (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumour Necrosis Factor Inhibition (TNFi-IR)
- EMEA Innovative Medicine
- Latest Phase 3 Data for First-in-Class TREMFYA®▼ (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to TNFI-IR
Latest Phase 3 Data for First-in-Class TREMFYA®▼ (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to TNFI-IR
- X (Twitter)
Copy link